Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
No aliases recorded.
Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.
Read the full article on WikipediaDiabetes mellitus type 2 Clinical criteria: The treatment must be used in combination with at least one of: metformin, a sulfonylurea, insulin, AND The condition must be inadequately responsive to at least one of: metformin, a sulfonylurea, insulin. Treatment criteria: Patient must not be undergoing concomitant PBS-subsidised treatment with any of: a GLP-1 receptor agonist, another DPP4 inhibitor.
“2.5 h (saxagliptin), 3.1 h (main metabolite)”
Working under the parallel aged-care framework? Aged-care equivalent →